These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 24093956

  • 1. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.
    Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta N, Yin D, Pan S, Liu J, Jiang H, Liu L.
    Mol Cancer; 2013 Oct 05; 12(1):114. PubMed ID: 24093956
    [Abstract] [Full Text] [Related]

  • 2. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
    Chao H, Wang L, Hao J, Ni J, Chang L, Graham PH, Kearsley JH, Li Y.
    Cancer Lett; 2013 Feb 01; 329(1):17-26. PubMed ID: 22995071
    [Abstract] [Full Text] [Related]

  • 3. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
    Li T, Dong ZR, Guo ZY, Wang CH, Zhi XT, Zhou JW, Li DK, Chen ZT, Chen ZQ, Hu SY.
    Liver Int; 2015 Apr 01; 35(4):1416-29. PubMed ID: 25066210
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
    Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, Lienlaf M, Atadja P, Seto E, Weber J, Sotomayor EM, Villagra A.
    Melanoma Res; 2013 Oct 01; 23(5):341-8. PubMed ID: 23963286
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.
    Edwards A, Li J, Atadja P, Bhalla K, Haura EB.
    Mol Cancer Ther; 2007 Sep 01; 6(9):2515-24. PubMed ID: 17876048
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
    Kubo M, Kanaya N, Petrossian K, Ye J, Warden C, Liu Z, Nishimura R, Osako T, Okido M, Shimada K, Takahashi M, Chu P, Yuan YC, Chen S.
    Breast Cancer Res Treat; 2013 Jan 01; 137(1):93-107. PubMed ID: 23160924
    [Abstract] [Full Text] [Related]

  • 14. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM.
    Breast Cancer Res; 2012 May 21; 14(3):R79. PubMed ID: 22613095
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. (-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma.
    Pei T, Meng Q, Han J, Sun H, Li L, Song R, Sun B, Pan S, Liang D, Liu L.
    Oncotarget; 2016 Jul 12; 7(28):43475-43491. PubMed ID: 27259268
    [Abstract] [Full Text] [Related]

  • 18. KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.
    Han J, Wang F, Lan Y, Wang J, Nie C, Liang Y, Song R, Zheng T, Pan S, Pei T, Xie C, Yang G, Liu X, Zhu M, Wang Y, Liu Y, Meng F, Cui Y, Zhang B, Liu Y, Meng X, Zhang J, Liu L.
    Oncogene; 2019 Jan 12; 38(3):406-420. PubMed ID: 30115976
    [Abstract] [Full Text] [Related]

  • 19. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
    Zheng T, Hong X, Wang J, Pei T, Liang Y, Yin D, Song R, Song X, Lu Z, Qi S, Liu J, Sun B, Xie C, Pan S, Li Y, Luo X, Li S, Fang X, Bhatta N, Jiang H, Liu L.
    Hepatology; 2014 Mar 12; 59(3):935-46. PubMed ID: 24037855
    [Abstract] [Full Text] [Related]

  • 20. The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis.
    Di Fazio P, Schneider-Stock R, Neureiter D, Okamoto K, Wissniowski T, Gahr S, Quint K, Meissnitzer M, Alinger B, Montalbano R, Sass G, Hohenstein B, Hahn EG, Ocker M.
    Cell Oncol; 2010 Jan 01; 32(4):285-300. PubMed ID: 20208142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.